» Articles » PMID: 12379623

Protection Against Tuberculosis: Cytokines, T Cells, and Macrophages

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2002 Oct 16
PMID 12379623
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

Tuberculosis remains a major health problem, with two million deaths and eight million new cases annually. At the same time, two billion people (one third of the total world population) are infected with the aetiological agent, Mycobacterium tuberculosis. Of these, fewer than 10% ever develop disease, although the pathogen is not eradicated but rather contained in discrete lesions. Hence, the immune system is highly effective in containing the pathogen, but fails to eradicate it. Disease typically develops through reactivation once the immune system is weakened. The immune response to M tuberculosis is T cell dependent. It comprises not only the conventional CD4 and CD8 T cells, but also gammadelta T cells and CD1 restricted T cells. gammadelta T cells recognise phospholigands and no presentation molecules are known thus far. CD1 restricted T cells recognise glycolipids, which are highly abundant components of the mycobacterial cell wall. Although different T cells are required for optimum protection, the immune mechanisms known to have a role in acquired resistance can be associated with two major mechanisms: (a) activation of macrophages by cytokines; (b) direct cytolytic activity. In vivo granuloma formation, which is central to protection, is induced and sustained by cytokines. Mycobacteria are contained within granulomas and in this way are prevented from spreading all over the body.

Citing Articles

Partial Loss of NEMO Function in a Female Carrier with No Incontinentia Pigmenti.

Cifaldi C, Sgrulletti M, Cesare S, Rivalta B, Emanuele A, Colucci L J Clin Med. 2025; 14(2.

PMID: 39860371 PMC: 11765721. DOI: 10.3390/jcm14020363.


Global proteomics reveals pathways of mesenchymal stem cells altered by Mycobacterium tuberculosis.

Kaur S, Angrish N, Vasudevan M, Khare G Sci Rep. 2024; 14(1):30677.

PMID: 39730375 PMC: 11680934. DOI: 10.1038/s41598-024-75722-5.


Human-immunodeficiency virus infection associated with the impaired Th1 and pro-inflammatory cytokine response in latent tuberculosis-infected individuals: A comparative cross-sectional study.

Girmay G, Kiflie A, Alem M, Lemma M, Bewket G PLoS One. 2024; 19(11):e0313306.

PMID: 39514524 PMC: 11548834. DOI: 10.1371/journal.pone.0313306.


Monocyte to Lymphocyte ratio is highly specific in diagnosing latent tuberculosis and declines significantly following tuberculosis preventive therapy: A cross-sectional and nested prospective observational study.

Mayito J, Meya D, Miriam A, Dhikusooka F, Rhein J, Sekaggya-Wiltshire C PLoS One. 2023; 18(11):e0291834.

PMID: 38033005 PMC: 10688757. DOI: 10.1371/journal.pone.0291834.


Bacterial dissemination in by CD+ T-cells & proinflammatory cytokines.

Davuluri K, Singh S, Chauhan D Indian J Med Res. 2023; 158(1):40-46.

PMID: 37602585 PMC: 10550058. DOI: 10.4103/ijmr.ijmr_2143_21.


References
1.
Maini R, St Clair E, Breedveld F, Furst D, Kalden J, Weisman M . Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 2000; 354(9194):1932-9. DOI: 10.1016/s0140-6736(99)05246-0. View

2.
Kaufmann S . Is the development of a new tuberculosis vaccine possible?. Nat Med. 2000; 6(9):955-60. DOI: 10.1038/79631. View

3.
Mohan V, Scanga C, Yu K, Scott H, Tanaka K, Tsang E . Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun. 2001; 69(3):1847-55. PMC: 98092. DOI: 10.1128/IAI.69.3.1847-1855.2001. View

4.
Flynn J, GOLDSTEIN M, Chan J, Triebold K, Pfeffer K, Lowenstein C . Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995; 2(6):561-72. DOI: 10.1016/1074-7613(95)90001-2. View

5.
Kaufmann S . How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol. 2002; 1(1):20-30. DOI: 10.1038/35095558. View